Reperfusion revisited: beyond TIMI 3 flow

Area of Science:

• Cardiology
• Vascular Biology
• Medical Therapeutics

Background:

• Acute myocardial infarction (AMI) therapy has evolved significantly since the 1980s, with early intravenous fibrinolytic therapy improving outcomes.
• Combining fibrinolysis and platelet lysis shows potential for enhanced infarct-related artery (IRA) patency, with large-scale mortality trials pending.
• Current research increasingly focuses on the myocardial microvasculature, recognizing that epicardial artery patency doesn't always ensure myocardial perfusion.

Purpose of the Study:

• To clarify the distinction between epicardial flow and myocardial malperfusion in acute myocardial infarction.
• To review contemporary evidence on microvascular function and obstruction in AMI.
• To provide insights into emerging therapeutic strategies for microvascular dysfunction in AMI.

Main Methods:

• Review of current literature on acute myocardial infarction therapeutics.
• Analysis of evidence comparing epicardial flow assessment with microvascular perfusion.
• Discussion of novel treatment approaches targeting microvascular obstruction.

Main Results:

• Epicardial artery patency (e.g., Thrombolysis In Myocardial Infarction [TIMI] flow) does not consistently correlate with actual myocardial perfusion.
• Advanced techniques are available to evaluate microvascular function beyond epicardial flow.
• Promising treatments for microvascular obstruction are emerging.

Conclusions:

• Understanding and addressing microvascular dysfunction is crucial for improving outcomes in acute myocardial infarction.
• Future therapeutic strategies for AMI should consider interventions targeting the microvasculature.
• Further research is needed to validate treatments aimed at improving myocardial reperfusion at the microvascular level.